Stock 6492 SENHWA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Senhwa Biosciences, Inc.

Equities

6492

TW0006492002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-05-14 EDT 		5-day change 1st Jan Change
41.7 TWD +0.24% Intraday chart for Senhwa Biosciences, Inc. +0.24% -18.07%
03-20 Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan CI
03-14 Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,358 4,804 20,164 9,329 5,140 4,540
Enterprise Value (EV) 1 4,129 3,974 17,815 7,312 3,537 3,230
P/E ratio -14.3 x -12.3 x -50.1 x -28.3 x -14.8 x -15.3 x
Yield - - - - - -
Capitalization / Revenue 7,310 x 16,012 x 32,681 x 16,962 x 5,140 x 4,540 x
EV / Revenue 5,632 x 13,247 x 28,873 x 13,294 x 3,537 x 3,230 x
EV / EBITDA -10.7 x -10.1 x -49.8 x -21.1 x -9.94 x -10.4 x
EV / FCF -17.1 x -16.6 x -125 x -41.1 x -12.9 x -17.3 x
FCF Yield -5.84% -6.03% -0.8% -2.43% -7.73% -5.79%
Price to Book 4.43 x 5.8 x 8.67 x 4.72 x 3.18 x 3.45 x
Nbr of stocks (in thousands) 74,417 74,476 89,618 89,704 88,628 89,186
Reference price 2 72.00 64.50 225.0 104.0 58.00 50.90
Announcement Date 19-03-28 20-03-24 21-03-29 22-03-11 23-03-30 24-03-14
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.733 0.3 0.617 0.55 1 1
EBITDA 1 -384.6 -391.5 -357.9 -345.9 -355.8 -309.5
EBIT 1 -387.5 -393.8 -359.3 -346.3 -356.1 -311.1
Operating Margin -52,860.57% -131,266.67% -58,226.74% -62,966.55% -35,611.5% -31,111.1%
Earnings before Tax (EBT) 1 -378.1 -389.7 -354.4 -328.3 -348.3 -295
Net income 1 -375.8 -391.4 -354.9 -329.3 -349.6 -296.3
Net margin -51,275.58% -130,475.33% -57,516.69% -59,864.91% -34,963.2% -29,630.6%
EPS 2 -5.050 -5.260 -4.493 -3.673 -3.920 -3.322
Free Cash Flow 1 -241.1 -239.8 -142.9 -177.8 -273.6 -187.1
FCF margin -32,887.74% -79,922.38% -23,159.44% -32,320.23% -27,361.89% -18,709.78%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-28 20-03-24 21-03-29 22-03-11 23-03-30 24-03-14
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales 1 0.15 0.1 0.25 0.25
EBITDA - - - -
EBIT 1 -89.43 -83.16 -78.6 -98.98
Operating Margin -59,619.33% -83,157% -31,438.4% -39,590.8%
Earnings before Tax (EBT) 1 -87.16 -81.63 -77.63 -97.59
Net income 1 -87.16 -82.54 -77.63 -97.59
Net margin -58,104% -82,538% -31,050.4% -39,037.6%
EPS 2 -0.9700 -0.9200 -0.8700 -1.090
Dividend per Share - - - -
Announcement Date 21-11-12 22-03-11 22-05-12 22-08-11
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,229 830 2,349 2,017 1,603 1,309
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -241 -240 -143 -178 -274 -187
ROE (net income / shareholders' equity) -27.1% -38.4% -22.5% -15.3% -19.5% -20.2%
ROA (Net income/ Total Assets) -16.9% -23.4% -13.8% -9.71% -12% -12.9%
Assets 1 2,229 1,674 2,572 3,390 2,919 2,300
Book Value Per Share 2 16.20 11.10 26.00 22.00 18.20 14.80
Cash Flow per Share 2 16.50 11.20 26.40 22.80 18.30 14.80
Capex 1 0.41 - 0.39 0.24 0.37 4.61
Capex / Sales 55.39% - 63.37% 43.09% 36.9% 460.5%
Announcement Date 19-03-28 20-03-24 21-03-29 22-03-11 23-03-30 24-03-14
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SENHWA BIOSCIENCES, INC. Stock Senhwa Biosciences, Inc.
-18.07% 115M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.52% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.38% 106B
BIONTECH SE Stock BioNTech SE
-12.64% 22.24B
ARGENX SE Stock argenx SE
+0.44% 21.25B
GENMAB A/S Stock Genmab A/S
-4.18% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.85% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.58% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.41% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-23.95% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6492 Stock
  4. Financials Senhwa Biosciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW